%20(1).svg)
Serán Featured Guest in Biospace Denatured Podcast: "Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?"
In the most recent episode of BioSpace's Podcast Denatured, "Will the IRA’s Focus on the Pharmaceutical Industry Hurt the World’s Healthcare System Instead of Helping Patients?", Serán CEO Dan Smithey, PhD alongside industry thought leaders address the topics of drug pricing, development costs, regulatory requirements and related impacts of the IRA.
Learn more by listening to this Biospace Insights podcast.
Joining this discussion are Industry experts:
Ali Pashazadeh, CEO, Treehill Partners
Dan Smithey, PhD, President, CEO and Co-founder, Serán BioScience
Matthew Price, COO and Co-founder, Promontory Therapeutics
Peter L. Rubin, Executive Director, No Patient Left Behind
Robert Williamson, President and COO, Triumvira Immunologics, Inc.
Listen on Spotify. Approximately 22 minutes listening time.
About Serán
Serán BioScience, LLC, is a science-driven drug development partner, recognized as a world leader in drug development. Utilizing a foundation of physical and chemical science, Serán designs robust formulations and engineered solutions to some of the industry's toughest drug product problems. Our experience and background cover a wide range of pharmaceutical manufacturing concepts bringing our world-class expertise to you and your drug product. Serán’s team has decades of experience developing complex drug molecules into enabling medicines. With every addition to our team, we further our commitment to our clients’ success. From preclinical to GMP and beyond, Serán is here to support you and your drug product every step of the way.
For more information, email us at hello@seranbio.com.
Contact
Brinette Holdren
Director of Marketing
Serán BioScience, LLC
63047 Layton Ave,
Bend, OR 97701 USA
Phone: (541)-237-8501
www.seranbio.com
.svg)